Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019

Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by...

Descripción completa

Detalles Bibliográficos
Autores principales: Razonable, Raymund R, Ganesh, Ravindra, Bishop, Rachel K, Culbertson, Tracy L, Destro Borgen, Molly, Hedin, Michelle C, Hopkins, Laura H, Jackson, Tammy A, Larsen, Jennifer J, Matoush, Jennifer A, Moehnke, Darcie E, Olson, Shelly M, Peterson, Kellie M, Rosedahl, Jordan, Philpot, Lindsey M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234828/
https://www.ncbi.nlm.nih.gov/pubmed/35769314
http://dx.doi.org/10.1177/23743735221105673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234828/
https://www.ncbi.nlm.nih.gov/pubmed/35769314
http://dx.doi.org/10.1177/23743735221105673

Ejemplares similares